Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
2 other identifiers
observational
1,000
1 country
1
Brief Summary
Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 10, 2024
CompletedFirst Posted
Study publicly available on registry
October 15, 2024
CompletedStudy Start
First participant enrolled
October 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 20, 2025
CompletedOctober 16, 2024
October 1, 2024
1 year
October 10, 2024
October 14, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of chemotherapy-related myelosuppression and current status of prophylactic therapy
The incidence and treatment status of chemotherapy-related myelosuppression were investigated in the form of questionnaires Like what： 1. Did bone marrow suppression occur after the previous cycle of chemotherapy? (First chemotherapy/occurrence/non-occurrence) 2. Did CIM (chemotherapy-induced myelosuppression) occur during this chemotherapy? (Multiple selections allowed) 3. Survey questions about existing CIM therapeutic drugs
2024.09-2025.09
Secondary Outcomes (8)
Incidence of chemotherapy-related myelosuppression
2024.09-2025.09
the rate and economic burden of neutropenia treatment during chemotherapy treatment
2024.09-2025.09
the incidence of thrombocytopenia and the rate of primary and secondary prevention and treatment during chemotherapy treatment
2024.09-2025.09
thrombocytopenia treatment rate and economic burden during chemotherapy treatment
2024.09-2025.09
the incidence and treatment rate of anemia during chemotherapy treatment;
2024.09-2025.09
- +3 more secondary outcomes
Study Arms (3)
Chemotherapy-Related Myelosuppression
Chemotherapy-Related Myelosuppression Clinical Management
Chemotherapy-related myelosuppression, primary prevention, treatment rate and clinical management
Chemotherapy-related myelosuppression, primary prevention, treatment rate and clinical management
Chemotherapy-induced myelosuppression, secondary prevention, treatment rates, and clinical managemen
no intervention
Interventions
No intervention
Eligibility Criteria
Chinese County-level Tumor Patients
You may qualify if:
- The confirmed malignant tumor is one of the non-small cell lung cancer/small cell lung cancer/breast cancer/gastric cancer/esophageal cancer/colorectal cancer/gynecological malignant tumor (ovarian cancer, cervical cancer, endometrial cancer).
- Patients who need to receive chemotherapy in the past 3 months and should continue to receive chemotherapy in the future
- The relevant diagnosis and treatment information involved in the survey is complete: only patients with at least 1-2 examination results after 1 week after chemotherapy can be included
- Understand and sign the informed consent form
- The chemotherapy regimen received for the most recent chemotherapy should be one of the following
- Non-small cell lung cancer TP scheme NP scheme DP scheme EP scheme GP scheme AP scheme Docetaxel/pemetrexed monotherapy Gemcitabine monotherapy Tigio monotherapy ADCs Other monotherapy or combination regimens containing platinum or taxane drugs Drug regimens that combine the above chemotherapy regimens (e.g., immunosuppressants, targeted therapy drugs, etc.)
- Small cell lung cancer with etoposide-containing combination regimens Platinum-containing combination regimens (except etoposide) Monotherapy or combination regimen containing topotecan, gemcitabine, paclitaxel Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)
- reast cancer ddEC sequential T regimen Anthracyclines and taxanes: TAC, TE, EC-T, ddEC-T, FEC-T regimens Combined taxane protocols: TP, AP, TC, Anthracycline combination regimen: EC, FEC Taxane monotherapy Yew combined with platinum Other platinum-containing regimens: NP, GP ADC drugs Microtubule inhibitors: NVB, taxanes (nab-paclitaxel, paclitaxel liposome, docetaxel), eutidrone, eribulin Microtubule inhibitors in combination with capecitabine Anthracycline monotherapy Drug regimens that combine the above chemotherapy (e.g., targeted therapy drugs, etc.)
- Gastric cancer SOX protocol XELOX scheme FOLFOX protocol DCF scheme ADCs Other monotherapy or combination regimens containing platinum or taxanes or fluorouracil Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)
- Esophageal cancer taxane + platinum regimen CF protocol DCF scheme FOLFOX protocol XELOX scheme FLOT scheme FOLFIRI PROTOCOL ECF protocol ECX scheme EOF scheme EOX protocol Other monotherapy or combination regimens containing platinum or taxane or fluorouracil Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)
- COLORECTAL CANCER FOLFOXIRI FOLFOX FOLFIRI XELOX Other monotherapy or combination regimens containing platinum or fluorouracil or raltitrexed Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)
- Gynecologic malignancies:platinum + taxane or its combination regimen Monotherapy or combination chemotherapy containing docetaxel/gemcitabine/topotecan/irinotecan Regimens (except platinum + taxanes) Other monotherapy or combination chemotherapy regimens containing platinum, taxanes, or anthracyclines
You may not qualify if:
- Patients with concurrent chemoradiotherapy,
- Patients with sequential chemoradiotherapy, and the irradiation site of radiotherapy is flat bone, sternum, and pelvis;
- Patients with active bleeding before or during treatment; If the patient has received targeted drugs such as CDK4/6 inhibitors or chidaaniline in the front-line treatment, which have a great impact on the blood phase, the drug can be discontinued for at least half a month before it can be included
- Patients who, in the opinion of other physicians, would cause non-chemotherapy-related myelosuppression
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The First Affiliated Hospital of Xinxiang Medical Collegelead
- Xinxiang Central Hospital of Henan provincecollaborator
- Linzhou People Hospitalcollaborator
- Inner Huang County Traditional Chinese Hospitalcollaborator
- Changyuan People Hospitalcollaborator
- Huojia County People Hospitalcollaborator
- Huojia County Alliance Hospitalcollaborator
- Qinyang People Hospitalcollaborator
- Xinan County People Hospitalcollaborator
- Henan Hongli Hospitalcollaborator
- Army Hospital of the 83rd Armycollaborator
- Anyang Cancer Hospitalcollaborator
- Puyang Hospital of Traditional Chinese Medicinecollaborator
- Puyang Huimin Hospitalcollaborator
- Hebi People Hospitalcollaborator
- The Second People Hospital of Xinxiang Henancollaborator
Study Sites (1)
The First Affiliated Hospital of Xinxiang Medical College
Xinxiang, Henan, 453000, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Ji YH yinghua, Dr.
The First Affiliated Hospital of Xinxiang Medical College
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 10, 2024
First Posted
October 15, 2024
Study Start
October 20, 2024
Primary Completion
October 20, 2025
Study Completion
December 20, 2025
Last Updated
October 16, 2024
Record last verified: 2024-10